University of Sheffield spinout company, Crucible Therapeutics, a biotechnology company developing novel therapies to treat amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD), has secured £5 million financing from Northern Gritstone and Argobio Studio.
